KR20220071175A - 소분자 PI4KIIIα 억제제 조성물, 이의 제조 방법 및 용도 - Google Patents

소분자 PI4KIIIα 억제제 조성물, 이의 제조 방법 및 용도 Download PDF

Info

Publication number
KR20220071175A
KR20220071175A KR1020227003749A KR20227003749A KR20220071175A KR 20220071175 A KR20220071175 A KR 20220071175A KR 1020227003749 A KR1020227003749 A KR 1020227003749A KR 20227003749 A KR20227003749 A KR 20227003749A KR 20220071175 A KR20220071175 A KR 20220071175A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
oil
pao
pi4kiiiα
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227003749A
Other languages
English (en)
Korean (ko)
Inventor
퓨드 후앙
펑 왕
슈 양
창핑 자오
샤오준 저우
Original Assignee
누오-베타 파마슈티컬 테크놀로지 (상하이) 씨오., 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 누오-베타 파마슈티컬 테크놀로지 (상하이) 씨오., 엘티디. filed Critical 누오-베타 파마슈티컬 테크놀로지 (상하이) 씨오., 엘티디.
Publication of KR20220071175A publication Critical patent/KR20220071175A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020227003749A 2019-07-05 2020-07-06 소분자 PI4KIIIα 억제제 조성물, 이의 제조 방법 및 용도 Ceased KR20220071175A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/094831 2019-07-05
CN2019094831 2019-07-05
PCT/CN2020/100377 WO2021004422A1 (zh) 2019-07-05 2020-07-06 小分子PI4KIIIα抑制剂组合物、其制备方法及用途

Publications (1)

Publication Number Publication Date
KR20220071175A true KR20220071175A (ko) 2022-05-31

Family

ID=74115038

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227003749A Ceased KR20220071175A (ko) 2019-07-05 2020-07-06 소분자 PI4KIIIα 억제제 조성물, 이의 제조 방법 및 용도

Country Status (15)

Country Link
US (1) US20230115711A1 (https=)
EP (1) EP3995134A4 (https=)
JP (1) JP2022538505A (https=)
KR (1) KR20220071175A (https=)
CN (2) CN118105372A (https=)
AU (1) AU2020309681A1 (https=)
BR (1) BR112022000155A2 (https=)
CA (1) CA3149104A1 (https=)
CO (1) CO2022001218A2 (https=)
IL (1) IL289586A (https=)
MX (1) MX2022000287A (https=)
PE (1) PE20220942A1 (https=)
PH (1) PH12022550254A1 (https=)
TW (1) TW202126294A (https=)
WO (1) WO2021004422A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685566A (zh) * 2020-12-31 2022-07-01 江苏挪贝肽医药科技有限公司 氧化苯砷晶型i、晶型ii和晶型iii及其制备方法
JP2024537837A (ja) * 2021-09-30 2024-10-16 ヌオ－ベータ・ファーマシューティカル・テクノロジー（シャンハイ）カンパニー・リミテッド ハロゲン化フェニルアルシンオキシド化合物およびその用途
CN116478954B (zh) * 2023-02-14 2025-06-10 中国农业大学 水稻基因OsPI4K及其在水稻抗稻瘟病中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365110A1 (en) * 2001-07-10 2003-07-15 Massachusetts Institute Of Technology Small molecule microarrays
EP2316943B1 (en) * 2007-07-05 2013-06-19 Novartis AG DSRNA for treating viral infection
WO2016172952A1 (zh) * 2015-04-30 2016-11-03 江苏挪贝肽医药科技有限公司 PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用
CN112437674A (zh) * 2018-04-11 2021-03-02 新墨西哥科技大学研究园公司 用于药物递送的脂质前药
BR112022019864A2 (pt) * 2020-03-31 2022-11-16 Nuo Beta Pharmaceutical Tech Shanghai Co Ltd Composto de oxofenilarsina deuterada e uso do mesmo
JP2024537837A (ja) * 2021-09-30 2024-10-16 ヌオ－ベータ・ファーマシューティカル・テクノロジー（シャンハイ）カンパニー・リミテッド ハロゲン化フェニルアルシンオキシド化合物およびその用途

Also Published As

Publication number Publication date
AU2020309681A1 (en) 2022-02-24
CO2022001218A2 (es) 2022-05-20
IL289586A (en) 2022-03-01
WO2021004422A1 (zh) 2021-01-14
CA3149104A1 (en) 2021-01-14
JP2022538505A (ja) 2022-09-02
EP3995134A4 (en) 2023-07-12
MX2022000287A (es) 2022-06-16
US20230115711A1 (en) 2023-04-13
EP3995134A1 (en) 2022-05-11
CN118105372A (zh) 2024-05-31
CN114555056B (zh) 2024-01-05
TW202126294A (zh) 2021-07-16
PE20220942A1 (es) 2022-05-31
PH12022550254A1 (en) 2023-06-26
CN114555056A (zh) 2022-05-27
BR112022000155A2 (pt) 2022-04-12

Similar Documents

Publication Publication Date Title
CA2866067C (en) Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
KR20220071175A (ko) 소분자 PI4KIIIα 억제제 조성물, 이의 제조 방법 및 용도
WO2022160970A1 (zh) 一种不含乙醇的难溶性药物浓缩液以及由其制备的胶束溶液
EP2528598B1 (en) Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent
CN108310390B (zh) 多西他赛亚油酸酯及其脂肪乳剂和应用
HK40074190A (en) MICROMOLECULE PI4KIIIα INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
HK40073830A (en) Micromolecule pi4kiiialpha inhibitor composition, preparation method therefor and use thereof
JPH03209377A (ja) Ｎｍｄａ遮断薬剤組成物
HK40074190B (zh) 小分子PI4KIIIα抑制剂组合物、其制备方法及用途
OA20568A (en) Micromolecule PI4Klllα inhibitor composition, preparation method therefor and use thereof.
EP3984989A1 (en) Ibuprofen ester prodrug, pharmaceutical composition and preparation method and use
CN109985004A (zh) 氟比洛芬酯脂肪乳注射液、其制备方法及应用
CN115531306B (zh) 一种注射用左奥硝唑衍生物乳状制剂及其制备方法
KR20240036651A (ko) 산화성 망막 질환의 진행을 억제하는 방법
SK284247B6 (sk) Lipozómový prípravok 6,9- bis[(2-aminoetyl)amino]benzo[g]izochinolín-5,10-dión dimaleátu a jeho použitie
WO2016033549A2 (en) (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
CN120004750B (zh) 一种无菌的双他喷他多癸二酸酯及其制备方法与用途
CN120058608B (zh) 可用于长效注射剂的喷他佐辛前药及制备方法与用途
CN114728882B (zh) 一种布洛芬酯衍生物及其乳状制剂
JP2025527136A (ja) 安定した注射カンナビジオール製剤
CA2880399C (en) Use of bimatoprost free acid administered to the skin to reduce adipose tissue
WO2022101678A2 (en) Lysophospholipid formulations
WO2022101841A1 (en) Solid dispersions of cannabidiol
KR20240109697A (ko) 나프토퀴논계 화합물을 포함하는 조성물 및 연질 캡슐 제형
CA2048856C (en) 15-deoxyspergualin suppository

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000